Cargando…

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients

BACKGROUND: BIBF 1120 is an oral, potent, tyrosine kinase inhibitor that simultaneously targets vascular endothelial growth factor receptors 1–3, platelet-derived growth factor receptors α and β, and fibroblast growth factor receptors 1–3, as well as FLT3 and Src. Currently, the molecule is in phase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bousquet, G, Alexandre, J, Le Tourneau, C, Goldwasser, F, Faivre, S, de Mont-Serrat, H, Kaiser, R, Misset, J L, Raymond, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242598/ https://www.ncbi.nlm.nih.gov/pubmed/22027711 http://dx.doi.org/10.1038/bjc.2011.440

Ejemplares similares

Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo
por: Xue, Cong, et al.
Publicado: (2016)

Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
por: Antoniu, Sabina A
Publicado: (2012)

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond
por: Gori, Bruno, et al.
Publicado: (2011)

BIBF1120 Protects against Diabetic Retinopathy through Neovascularization-Related Molecules and the MAPK Signaling Pathway
por: Cao, Xin, et al.
Publicado: (2023)

PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120
por: Fazio, Grazia, et al.
Publicado: (2022)

Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl(4)-induced liver fibrogenesis mouse model
por: Öztürk Akcora, Büsra, et al.
Publicado: (2017)

Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120)
por: Huang, Ruby Yun-Ju, et al.
Publicado: (2015)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole
por: Gunzer, Katharina, et al.
Publicado: (2016)

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
por: Galli, L, et al.
Publicado: (2007)

Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
por: Chi, Chenfei, et al.
Publicado: (2022)

A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer
por: Zhou, Tie, et al.
Publicado: (2015)

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer
por: Heath, Elisabeth, et al.
Publicado: (2019)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Sinibaldi, Victoria J
Publicado: (2007)

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
por: Hu, Linjun, et al.
Publicado: (2020)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Innovative In Vitro Chemo-Hormonal Drug Therapy for Refractory Thyroid Carcinomas
por: Sung, Tae-Yon, et al.
Publicado: (2012)

Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
por: Tsakalozou, Eleftheria, et al.
Publicado: (2012)

P1120: NOVEL TARGETED AGENTS IN COMBINATION WITH R-ICE (R-ICE-X) BASED ON GENOTYPING IN RELAPSED/REFRACTORY DLBCL.
por: Yige, Shen, et al.
Publicado: (2023)

P1120: THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA
por: Liu, A., et al.
Publicado: (2022)

Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
por: Maj-Hes, Agnieszka, et al.
Publicado: (2021)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

New 11,20-Epoxybriaranes from the Gorgonian Coral Junceella fragilis (Ellisellidae)
por: Lin, Chia-Cheng, et al.
Publicado: (2019)

Abstract: 11.20 The Potential Of Adipose Derived Stem Cells For Chronic Wounds
por: Rafik, Amine, et al.
Publicado: (2017)

Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles
por: Kramer, G, et al.
Publicado: (2006)

Triple-tyrosine kinase inhibition by BIBF1000 attenuates airway and pulmonary arterial remodeling following chronic allergen challenges in mice
por: Gurusamy, Malarvizhi, et al.
Publicado: (2023)

1120. Reliability of Parent-Reported Pediatric Antibiotic Use in a Longitudinal Birth Cohort
por: D’Arinzo, Lauren, et al.
Publicado: (2019)

Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer : Comparative Analysis between 1st-line and 2nd-line Docetaxel
por: Joung, Jae Young, et al.
Publicado: (2008)

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
por: Collins, R, et al.
Publicado: (2006)

Clinical pharmacodynamic factors in docetaxel toxicity
por: Puisset, F, et al.
Publicado: (2007)

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility
por: Crawford, E. David, et al.
Publicado: (2017)

Evaluation of forensic and anthropological potential of D9S1120 in Mestizos and Amerindian populations from Mexico
por: Rangel-Villalobos, Héctor, et al.
Publicado: (2012)

1120. Impact of Training Residents to Improve HIV Screening in a Teaching Hospital in Mexico City
por: Guerrero-Torres, Lorena, et al.
Publicado: (2020)

Co-treatment by docetaxel and vinblastine breaks down P-glycoprotein mediated chemo-resistance
por: Mohseni, Mahsa, et al.
Publicado: (2016)

Chemo-Enzymatic Synthesis of Ester-Linked Docetaxel-Monosaccharide Conjugates as Water-Soluble Prodrugs
por: Shimoda, Kei, et al.
Publicado: (2011)

Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate
por: Amato, Robert J., et al.
Publicado: (2008)

11,20-Dihydroxy-3-oxopregna-1,4-dien-21-oic acid monohydrate
por: Guo, Zhanqiang, et al.
Publicado: (2011)

The outcomes of 1120 severe multiple trauma patients with hemorrhagic shock in an emergency department: a retrospective study
por: Wen, Yin, et al.
Publicado: (2013)

1120 The Impact of Influenza Vaccination in Patients with Cancer on Subsequent Disease during the 2013-2014 Influenza Season
por: Azzi, Jacques, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cjfml60d73igbm31jlhmk5eq9e